PD-1 Immune Checkpoint Inhibitor Therapy Malignant Tumor Based on Monotherapy and Combined Treatment Research. (23rd March 2021)

• Record Type: Journal Article
• Authors: Zhang, Yu; Mou, Guang-Ze; Li, Tian-Zhu; Xu, Wan-Ting; Zhang, Tong; Xue, Hui; Zuo, Wen-Bo; Li, Yan-Nan; Luo, Ying-Hua; Jin, Cheng-Hao
• Is Part Of: Technology in cancer research & treatment. Volume 20(2021)
• Publication Date: 2021-03-23
• Subjects: PD-1 -- PD-L1 -- anti-tumor -- mechanism -- immunotherapy; Oncology -- Periodicals; Cancer -- Diagnosis -- Periodicals; Cancer -- Treatment -- Technological innovations -- Periodicals; 616.994
• DOI: 10.1177/15330338211004942
• Languages: English
• ISSNs: 1533-0346

Abstract

Recently, immunotherapy has become the fourth pillar of cancer treatment in addition to surgery therapy, chemotherapy, and radiation therapy. The inhibitors of programed cell death protein 1 (PD-1) and its ligand PD-L1 are the new stars in immunotherapy, as they can overcome tumor immunosuppression. However, the efficacy of PD-1 inhibitors still needs to be further developed for clinical treatment. Therefore, research into treatment with anti-PD-1 drugs has emerged as a new development field. This review provides novel insights into the role and mechanism of PD-1 combination anti-tumor therapy, thereby promoting its clinical application in anti-tumor immunotherapy.